CN107684608A - A kind of Chinese medicine composition for treating lupus nephritis and preparation method thereof - Google Patents
A kind of Chinese medicine composition for treating lupus nephritis and preparation method thereof Download PDFInfo
- Publication number
- CN107684608A CN107684608A CN201710962757.2A CN201710962757A CN107684608A CN 107684608 A CN107684608 A CN 107684608A CN 201710962757 A CN201710962757 A CN 201710962757A CN 107684608 A CN107684608 A CN 107684608A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- lupus nephritis
- medicine composition
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/235—Foeniculum (fennel)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Abstract
The invention discloses a kind of Chinese medicine composition for treating lupus nephritis and preparation method thereof, said composition is prepared by the raw material of following parts by weight：15 20 parts of smilax, 12 15 parts of barrenwort, 12 15 parts of jatamans valeriana rhizome, 36 parts of the fleece-flower root, 8 10 parts of raspberry, 15 20 parts of the Radix Astragali, 69 parts of radix glycyrrhizae, 48 parts of Gorgon fruit, 5 10 parts of pseudo-ginseng, 10 12 parts of Milk Thistle grass, 36 parts of fennel seeds, 10 12 parts of hypericum japonicum, 5 10 parts of cordate houttuynia, flea stop 13 parts, 69 parts of Radix Codonopsis, 4 10 parts of rhizoma imperatae, 5 10 parts of pittosporum illicioides, 36 parts of tassel flower, 36 parts of lycium ruthenicum.The composition of the present invention is evident in efficacy to treatment lupus nephritis, has and mends nourishing liver and kidney, clearing heat and detoxicating, dispelling wind and removing obstruction in the meridians, blood stasis-eliminating and stagnation-dissipating, spleen-benefiting mind-tranquilizing, promoting blood circulation and removing blood stasis and other effects.
Description
Technical field
The present invention relates to field of traditional Chinese, and in particular to a kind of Chinese medicine composition for treating lupus nephritis and its preparation
Method.
Background technology
Lupus nephritis refers to that systemic loupus erythematosus (SLE) merges the immunity infringement of double kidney different pathological types, together
When with obvious kidney damage clinical manifestation a kind of disease.Its fall ill formed with immune complex, immunocyte and cell because
The dysimmunities such as son are relevant.In addition to SLE general manifestations, clinic is mainly shown as blood urine, albuminuria, renal insufficiency etc..It is
A kind of multifactor specific autoimmune diseases for including the participations such as heredity, sex hormone, environment, infection, medicine, immune response.On
Many factors interaction is stated, causes body immune system disorderly, most important of which is characterized in that generation antinuclear antibodies etc. is a variety of
Autoantibody, the latter forms immune complex with antigen, and with dysimmunities such as immunocyte, cell factors, this is SLE more
Tissue, the Common Mechanism of organ damage.
The pathogenesis of lupus nephritis may be relevant with following factor：1. CIC ELISA is in renal deposition；②
Immune complex in situ is formed；3. local complement activates；4. the direct effect of autoantibody；5. the immune response of T cell mediation
Deng.The general manifestation of lupus nephritis is generated heat for interruption, and cheekbone portion erythema (butterfly erythema), plate-like erythema, photosensitization, oral cavity is burst
Ulcer, arthritis, scrositis, nervous system abnormality (twitch or mental disease).Kidney shows as simple hematuria or albuminuria, blood
Urine, albuminuria show with oedema, the soreness of waist or hypertension, i.e. ephritis sample；High-grade Proteinuria, Hypoproteinemia, oedema, i.e. nephrosis are comprehensive
Simulator sickness sample shows；Blood urine, albuminuria drastically decline with renal function, are showed in radical property ephritis；Renal interstitial lesion；Chronic kidney
Exhaustion.
Lupus nephritis is still a kind of unknown property disease of reason at present, and the main purpose for the treatment of is the activity for controlling LN,
Renal function is protected, delays the process of renal fibrosis.For the light-duty SLE and systemic lupus erythematosus that target organ function is normal or stable
Nephritis patient, as one sees fit with non-steroid anti-inflammatory drug or antimalarial, can in short-period used, low dose of glucocorticoid (such as prednisone
20~40mg/d), if necessary plus use immunodepressant.The heavy SLE and systemic lupus erythematosus for occurring substantially damaging for important target organ
Nephritis patient, glomerulonephritis continues not alleviate, rapidly progressing glomerulonephritis, Patients With Nephrotic Symdrome, should give standard hormon
Treat (metacortandracin 1g/kg/d) and immunosuppressant treatment, for acute threat to life heavy lupus patient should give it is sharp
Plain impact treatment (0.5~1.0g/d of methylprednisolone).When above method less effective or the heavier state of an illness, it is contemplated that plasma exchange
Therapy.It should promptly be dialysed during with acute serious renal insufficiency, serious Hypervolemia, heart failure, it is left on pass.
Therefore, the reliable medicine of curative effect is clinically still lacked at present in general.
The content of the invention
To solve the above problems, the invention provides a kind of Chinese medicine composition for treating lupus nephritis and its preparation side
Method, the composition of gained is evident in efficacy to treatment lupus nephritis, and there is benefit nourishing liver and kidney, clearing heat and detoxicating, dispelling wind and removing obstruction in the meridians, stagnation resolvation to dissipate
Knot, spleen-benefiting mind-tranquilizing, promoting blood circulation and removing blood stasis and other effects.
To achieve the above object, the technical scheme taken of the present invention is：
A kind of Chinese medicine composition for treating lupus nephritis, is prepared by the raw material of following parts by weight：
Smilax 15-20 parts, barrenwort 12-15 parts, jatamans valeriana rhizome 12-15 parts, fleece-flower root 3-6 parts, raspberry 8-10 parts, Huang
Stilbene 15-20 parts, radix glycyrrhizae 6-9 parts, Gorgon fruit 4-8 parts, pseudo-ginseng 5-10 parts, Milk Thistle grass 10-12 parts, fennel seeds 3-6 parts, hypericum japonicum 10-
12 parts, cordate houttuynia 5-10 parts, flea stop 1-3 parts, Radix Codonopsis 6-9 parts, rhizoma imperatae 4-10 parts, pittosporum illicioides 5-10 parts, tassel flower 3-6 parts,
Lycium ruthenicum 3-6 parts.
Preferably, it is prepared by the raw material of following parts by weight：
15 parts of smilax, 12 parts of barrenwort, 12 parts of jatamans valeriana rhizome, 3 parts of the fleece-flower root, 8 parts of raspberry, 15 parts of the Radix Astragali, radix glycyrrhizae 6
Part, 4 parts of Gorgon fruit, 5 parts of pseudo-ginseng, 10 parts of Milk Thistle grass, 3 parts of fennel seeds, 10 parts of hypericum japonicum, 5 parts of cordate houttuynia, flea stop 1 part, 6 parts of Radix Codonopsis,
4 parts of rhizoma imperatae, 5 parts of pittosporum illicioides, 3 parts of tassel flower, 3 parts of lycium ruthenicum.
Preferably, it is prepared by the raw material of following parts by weight：
20 parts of smilax, 15 parts of barrenwort, 15 parts of jatamans valeriana rhizome, 6 parts of the fleece-flower root, 10 parts of raspberry, 20 parts of the Radix Astragali, radix glycyrrhizae 9
Part, 8 parts of Gorgon fruit, 10 parts of pseudo-ginseng, 12 parts of Milk Thistle grass, 6 parts of fennel seeds, 12 parts of hypericum japonicum, 10 parts of cordate houttuynia, flea stop 3 parts, Radix Codonopsis 9
Part, 10 parts of rhizoma imperatae, 10 parts of pittosporum illicioides, 6 parts of tassel flower, 6 parts of lycium ruthenicum.
Preferably, it is prepared by the raw material of following parts by weight：
17.5 parts of smilax, 13.5 parts of barrenwort, 13.5 parts of jatamans valeriana rhizome, 4.5 parts of the fleece-flower root, 9 parts of raspberry, the Radix Astragali 17.5
Part, 7.5 parts of radix glycyrrhizae, 6 parts of Gorgon fruit, 7.5 parts of pseudo-ginseng, 11 parts of Milk Thistle grass, 4.5 parts of fennel seeds, 11.5 parts of hypericum japonicum, cordate houttuynia 7.5
Part, flea stop 2 parts, 7.5 parts of Radix Codonopsis, 7 parts of rhizoma imperatae, 7.5 parts of pittosporum illicioides, 4.5 parts of tassel flower, 4.5 parts of lycium ruthenicum.
Present invention also offers a kind of above-mentioned preparation method for the Chinese medicine composition for treating lupus nephritis, including following step
Suddenly：
S1, by above-mentioned formula weigh each component；
S2, by each component clean drain after be placed in steam-explosion jar, it is 0.7- to be first passed through nitrogen to steam explosion pressure inside the tank
1.7MPa, explosion treatment 10-25min；Then it is 2.7-3.7MPa to be passed through steam to steam explosion pressure inside the tank rapidly, at steam blasting
After managing 3-5min, room temperature is concentrated into relative density 1.10-1.20, obtains concentrate；
S3, to by mass percentage be 0.5-2% ratio neutral proteinase, 30-35 are added into the concentrate of gained
0.5-1h is digested at DEG C, filters, obtains enzymolysis liquid；
S3, by naturally to thaw again after the enzymolysis liquid quick freeze of gained, precipitate age of starch in extract；Collect supernatant
Liquid, remainder centrifugation, collect centrifugal liquid and be incorporated in supernatant；
S4, by supernatant with 3-7BV/h flow velocity by macroporous resin column, after Dynamic Adsorption saturation, given birth to epidermal cell
It is colourless to efflux that the long factor with 5-8BV/h flow velocity elutes above-mentioned macroporous resin column, then with volume fraction is 50%-70%'s
Organic solvent is eluted with 8-12BV/h flow velocity, is collected eluent, is concentrated under reduced pressure, obtains medicinal extract；
S5, medicinal extract is dissolved with water after with 3-5BV/h flow velocity by polyamide column, after Dynamic Adsorption saturation, use 3-7BV
Epithelical cell growth factor elutes above-mentioned polyamide column with 2-10BV/h flow velocity, then with volume fraction is having for 30%-50%
The solvent aqueous solution is eluted with 5-10BV/h flow velocity, and collection has eluent, is spray-dried, is produced composition.
The organic solvent is the turpentine derivatives of natural origin, and the turpentine derivatives are the isomery of firpene, disproportionation
Product.
The invention has the advantages that：
Based on kidney tonifying and detoxicating, supplemented by function of warming yang and gore removing, physical function is integrated from many aspects such as liver,spleen,kidneys
Conditioning, so as to significantly improve the immunity of human body, reduce Urine proteins；Used major pharmaceutical agent is natural plant
Thing, harmless to the body, long-term use is not in side effect and dependence；Using steam explosion, enzymolysis, macroporous resin adsorption and have
The mode that solvent elution is combined is processed to medicinal material so that and the active ingredient in medicinal material can be separated out fully, so that
On the premise of ensureing curative effect of medicine, the side effect of medicament is further reduced.
Embodiment
In order that objects and advantages of the present invention are more clearly understood, the present invention is carried out with reference to embodiments further
Describe in detail.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, it is not used to limit this hair
It is bright.
Embodiment 1
A kind of Chinese medicine composition for treating lupus nephritis, is prepared by the raw material of following parts by weight：
15 parts of smilax, 12 parts of barrenwort, 12 parts of jatamans valeriana rhizome, 3 parts of the fleece-flower root, 8 parts of raspberry, 15 parts of the Radix Astragali, radix glycyrrhizae 6
Part, 4 parts of Gorgon fruit, 5 parts of pseudo-ginseng, 10 parts of Milk Thistle grass, 3 parts of fennel seeds, 10 parts of hypericum japonicum, 5 parts of cordate houttuynia, flea stop 1 part, 6 parts of Radix Codonopsis,
4 parts of rhizoma imperatae, 5 parts of pittosporum illicioides, 3 parts of tassel flower, 3 parts of lycium ruthenicum.
Embodiment 2
A kind of Chinese medicine composition for treating lupus nephritis, is prepared by the raw material of following parts by weight：
20 parts of smilax, 15 parts of barrenwort, 15 parts of jatamans valeriana rhizome, 6 parts of the fleece-flower root, 10 parts of raspberry, 20 parts of the Radix Astragali, radix glycyrrhizae 9
Part, 8 parts of Gorgon fruit, 10 parts of pseudo-ginseng, 12 parts of Milk Thistle grass, 6 parts of fennel seeds, 12 parts of hypericum japonicum, 10 parts of cordate houttuynia, flea stop 3 parts, Radix Codonopsis 9
Part, 10 parts of rhizoma imperatae, 10 parts of pittosporum illicioides, 6 parts of tassel flower, 6 parts of lycium ruthenicum.
Embodiment 3
A kind of Chinese medicine composition for treating lupus nephritis, is prepared by the raw material of following parts by weight：
17.5 parts of smilax, 13.5 parts of barrenwort, 13.5 parts of jatamans valeriana rhizome, 4.5 parts of the fleece-flower root, 9 parts of raspberry, the Radix Astragali 17.5
Part, 7.5 parts of radix glycyrrhizae, 6 parts of Gorgon fruit, 7.5 parts of pseudo-ginseng, 11 parts of Milk Thistle grass, 4.5 parts of fennel seeds, 11.5 parts of hypericum japonicum, cordate houttuynia 7.5
Part, flea stop 2 parts, 7.5 parts of Radix Codonopsis, 7 parts of rhizoma imperatae, 7.5 parts of pittosporum illicioides, 4.5 parts of tassel flower, 4.5 parts of lycium ruthenicum.
The embodiment of the present invention additionally provides a kind of preparation method for the Chinese medicine composition for treating lupus nephritis, including as follows
Step：
S1, the formula as described in embodiment 1, embodiment 2 and embodiment 3 weigh each component；
S2, by each component clean drain after be placed in steam-explosion jar, it is 0.7- to be first passed through nitrogen to steam explosion pressure inside the tank
1.7MPa, explosion treatment 10-25min；Then it is 2.7-3.7MPa to be passed through steam to steam explosion pressure inside the tank rapidly, at steam blasting
After managing 3-5min, room temperature is concentrated into relative density 1.10-1.20, obtains concentrate；
S3, to by mass percentage be 0.5-2% ratio neutral proteinase, 30-35 are added into the concentrate of gained
0.5-1h is digested at DEG C, filters, obtains enzymolysis liquid；
S3, by naturally to thaw again after the enzymolysis liquid quick freeze of gained, precipitate age of starch in extract；Collect supernatant
Liquid, remainder centrifugation, collect centrifugal liquid and be incorporated in supernatant；
S4, by supernatant with 3-7BV/h flow velocity by macroporous resin column, after Dynamic Adsorption saturation, given birth to epidermal cell
It is colourless to efflux that the long factor with 5-8BV/h flow velocity elutes above-mentioned macroporous resin column, then with volume fraction is 50%-70%'s
Organic solvent is eluted with 8-12BV/h flow velocity, is collected eluent, is concentrated under reduced pressure, obtains medicinal extract；
S5, medicinal extract is dissolved with water after with 3-5BV/h flow velocity by polyamide column, after Dynamic Adsorption saturation, use 3-7BV
Epithelical cell growth factor elutes above-mentioned polyamide column with 2-10BV/h flow velocity, then with volume fraction is having for 30%-50%
The solvent aqueous solution is eluted with 5-10BV/h flow velocity, and collection has eluent, is spray-dried, is produced composition；It is described to have
Solvent is the turpentine derivatives of natural origin, and the turpentine derivatives are isomery, the disproportionation products of firpene.
Experimental example
Experimental animal and packet：
8 week old systemic loupus erythematosus (SLE) MRL/Ipr mouse 50 are taken, female, after adaptability is raised one week, by body
5 groups, every group 10 are randomly divided into again.ICR mouse 10, female, as Normal group mouse.
Normal group：Gavage gives solvent；
SLE model groups：Gavage gives solvent；
Metacortandracin group：Gavage gives 5mg/kg；
Chinese medicine composition low dose group：Gavage gives the medicine 0.5g/kg prepared by the formula of the embodiment of the present invention 3；
Chinese medicine composition middle dose group：Gavage gives the medicine 1g/kg prepared by the formula of the embodiment of the present invention 3；
Chinese medicine composition high dose group：Gavage gives the medicine 4g/kg prepared by the formula of the embodiment of the present invention 3.
All test groups are administered once daily, and successive administration 3 weeks, are taken blood standby at the end of administration, are won spleen.
Lymphocyte subgroup is analyzed
The preparation of Single-cell suspensions：The spleen of mouse is put into the culture dish for filling cold PBS liquid and cleaned, use glass
3ml PBS grindings are added in glass homogenizer, then are filtered with 200 mesh stainless (steel) wires, Splenic vessel liquid is centrifuged with rotating speed 1500rpm/
Min is centrifuged 7 minutes, abandons supernatant, and adds erythrocyte cracked liquid 2.5ml, is mixed, and PBS liquid 2ml is added after standing 2 minutes
Cracking reaction is terminated, then is centrifuged 7 minutes with 1500rpm/min, abandoning supernatant, is washed with PBS and adds PBS afterwards three times, in fluorescence
Cell number is calculated under microscope.Operation above is both needed on ice.With above Single-cell suspensions, after counting cell number,
5 × 106cells/ml of cell concentration adjustment concentration.Each group takes a wherein mouse boosting cell sample to do subgroup analysis,
The mouse boosting cell sample for adjusting concentration adds flow cytometry dedicated pipe, and every mouse boosting cell sample preparation two is managed, often
Pipe adds the μ l of sample 100.In the first pipe plus 5 μ l CD3 (FITC) and 3 μ l CD4 (PE) containing sample dedicated pipe, the second pipe adds
5 μ l CD3 (FITC) and 3 μ l CD8 (PE).Room temperature black out is incubated 20min, and each pipe adds 500 μ l sheath fluids, vibration upper machine after mixing
Analysis.
The measure of microdose urine protein
Experiment reagent：10% (v/v) glacial acetic acid solution (PH2.8)；0.303mol/L glycine-glacial acetic acid buffer solution
(PH3.0)：22.72g glycine is weighed, 1000ml is diluted to 10% glacial acetic acid solution, adds NaN3100mg, Room-temperature seal can
Stablize 1 year；Bromophenol blue (1.924mmol/L) stores liquid：257,36mgBPB accurately is weighed, it is molten to 200ml with absolute ethyl alcohol, 4 DEG C
Refrigerator can be stablized 1 year；Bromophenol blue (0.231mmol/L) developer：Take 60ml BPB to store liquid, add 2.5ml TritonX-
100,500ml is diluted to glycine-glacial acetic acid buffer solution, Room-temperature seal can preserve 1 year.
The collection and detection of sample：Mouse is put in metabolic cage respectively in the 20th day and raised, collects 12 hours overnight and urinates,
Accurate recording urine volume.After Sodium azide processing, (2000r/min) 10min is centrifuged, measures the mouse urine 2ml of storage, respectively plus is developed the color
Agent 1ml, mix (preventing bubble), absorbance A is determined under 600nm with ultraviolet specrophotometer.Absorbance A reflection urine is micro-
The content size of albumin is measured, A values are smaller, and microdose urine protein content is lower.
The measure of serum IL -10, anti-ds-DNA antibody content
Measure is completed by operating instruction using commercially available serum IL -10, anti-ds-DNA antibody content kit.
After testing, composition of the invention can correct the imbalance state of SLE mouse T cell subgroups.With Normal group
Compare, the IL-10 and anti-ds-DNA antibody level of SLE model mices are significantly raised, and compared with SLE model groups, the present invention can show
Writing reduces SLE mice serums IL-10 and anti-ds-DNA antibody level, and wherein Chinese medicine composition is low, middle dose group effect is particularly aobvious
Write, better than positive drug, wherein there was no significant difference with Normal group for Chinese medicine composition middle dose group.This shows, of the invention
Medicine is notable for SLE mouse therapeutic effects.
In t lymphocyte subset cluster analysis experiment, compared with SLE model groups, the present invention can make what SLE samples mouse declined
CD3+CD4+T cells rise, and decline the CD3+CD8+T of rising, correct the imbalance state of T cell subgroup；Serum IL -10,
Anti-ds-DNA antibody assay experiment in, compared with SLE model groups, the present invention can significantly reduce SLE mice serums IL-10 and
The horizontal rise of anti-ds-DNA antibody, wherein there was no significant difference with Normal group for Chinese medicine composition middle dose group, illustrates this
The medicine of invention is notable for SLE mouse therapeutic effects；In the determination test of microdose urine protein, SLE model group albumin
Content is significantly raised, and reflection SLE mouse kidneys have damage, and the present invention can significantly reduce the content of albumin in SLE mouse urines,
Chinese medicine composition is low, middle dose group effect is especially pronounced, better than positive drug, and Chinese medicine composition is low, middle dose group with it is normal
There was no significant difference for control group, shows the medicine of the present invention for therapeutic effect of the SLE mouse kidneys damage with protrusion.
Described above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (6)
1. a kind of Chinese medicine composition for treating lupus nephritis, it is characterised in that be prepared by the raw material of following parts by weight：
Smilax 15-20 parts, barrenwort 12-15 parts, jatamans valeriana rhizome 12-15 parts, fleece-flower root 3-6 parts, raspberry 8-10 parts, the Radix Astragali
15-20 parts, radix glycyrrhizae 6-9 parts, Gorgon fruit 4-8 parts, pseudo-ginseng 5-10 parts, Milk Thistle grass 10-12 parts, fennel seeds 3-6 parts, hypericum japonicum 10-12
Part, cordate houttuynia 5-10 parts, flea stop 1-3 parts, Radix Codonopsis 6-9 parts, rhizoma imperatae 4-10 parts, pittosporum illicioides 5-10 parts, tassel flower 3-6 parts, black
Matrimony vine 3-6 parts.
2. a kind of Chinese medicine composition for treating lupus nephritis as claimed in claim 1, it is characterised in that by following parts by weight
Raw material be prepared：
15 parts of smilax, 12 parts of barrenwort, 12 parts of jatamans valeriana rhizome, 3 parts of the fleece-flower root, 8 parts of raspberry, 15 parts of the Radix Astragali, 6 parts of radix glycyrrhizae, Gorgon euryale
Real 4 parts, 5 parts of pseudo-ginseng, 10 parts of Milk Thistle grass, 3 parts of fennel seeds, 10 parts of hypericum japonicum, 5 parts of cordate houttuynia, flea stop 1 part, 6 parts of Radix Codonopsis, cogongrass
4 parts of root, 5 parts of pittosporum illicioides, 3 parts of tassel flower, 3 parts of lycium ruthenicum.
3. a kind of Chinese medicine composition for treating lupus nephritis as claimed in claim 1, it is characterised in that by following parts by weight
Raw material be prepared：
20 parts of smilax, 15 parts of barrenwort, 15 parts of jatamans valeriana rhizome, 6 parts of the fleece-flower root, 10 parts of raspberry, 20 parts of the Radix Astragali, 9 parts of radix glycyrrhizae, Gorgon euryale
Real 8 parts, 10 parts of pseudo-ginseng, 12 parts of Milk Thistle grass, 6 parts of fennel seeds, 12 parts of hypericum japonicum, 10 parts of cordate houttuynia, flea stop 3 parts, it is 9 parts of Radix Codonopsis, white
10 parts of lalang grass rhizome, 10 parts of pittosporum illicioides, 6 parts of tassel flower, 6 parts of lycium ruthenicum.
4. a kind of Chinese medicine composition for treating lupus nephritis as claimed in claim 1, it is characterised in that by following parts by weight
Raw material be prepared：
17.5 parts of smilax, 13.5 parts of barrenwort, 13.5 parts of jatamans valeriana rhizome, 4.5 parts of the fleece-flower root, 9 parts of raspberry, 17.5 parts of the Radix Astragali,
7.5 parts of radix glycyrrhizae, 6 parts of Gorgon fruit, 7.5 parts of pseudo-ginseng, Milk Thistle grass 11 parts, 4.5 parts of fennel seeds, 11.5 parts of hypericum japonicum, 7.5 parts of cordate houttuynia,
Flea stop 2 parts, 7.5 parts of Radix Codonopsis, 7 parts of rhizoma imperatae, 7.5 parts of pittosporum illicioides, 4.5 parts of tassel flower, 4.5 parts of lycium ruthenicum.
5. a kind of preparation method for the Chinese medicine composition for treating lupus nephritis, it is characterised in that comprise the following steps：
S1, the formula as described in claim any one of 1-4 weigh each component；
S2, by each component clean drain after be placed in steam-explosion jar, it is 0.7-1.7MPa to be first passed through nitrogen to steam explosion pressure inside the tank, quick-fried
Tear manages 10-25min；Then it is 2.7-3.7MPa, Steam explosion treatment 3-5min to be passed through steam to steam explosion pressure inside the tank rapidly
Afterwards, room temperature is concentrated into relative density 1.10-1.20, obtains concentrate；
S3, to being that 0.5-2% ratio adds neutral proteinase into the concentrate of gained by mass percentage, at 30-35 DEG C
0.5-1h is digested, filtering, obtains enzymolysis liquid；
S3, by naturally to thaw again after the enzymolysis liquid quick freeze of gained, precipitate age of starch in extract；Collect supernatant,
Remainder centrifuges, and collects centrifugal liquid and is incorporated in supernatant；
S4, by supernatant with 3-7BV/h flow velocity by macroporous resin column, after Dynamic Adsorption saturation, with epidermal growth because
It is colourless to efflux that son with 5-8BV/h flow velocity elutes above-mentioned macroporous resin column, then with volume fraction is the organic of 50%-70%
Solvent is eluted with 8-12BV/h flow velocity, is collected eluent, is concentrated under reduced pressure, obtains medicinal extract；
S5, medicinal extract is dissolved with water after with 3-5BV/h flow velocity by polyamide column, after Dynamic Adsorption saturation, with 3-7BV epidermises
Porcine HGF elutes above-mentioned polyamide column with 2-10BV/h flow velocity, then with volume fraction is the organic molten of 30%-50%
The agent aqueous solution is eluted with 5-10BV/h flow velocity, and collection has eluent, is spray-dried, is produced composition.
A kind of 6. preparation method for the Chinese medicine composition for treating lupus nephritis as claimed in claim 5, it is characterised in that institute
The turpentine derivatives that organic solvent is natural origin are stated, the turpentine derivatives are isomery, the disproportionation products of firpene.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710962757.2A CN107684608A (en) | 2017-10-02 | 2017-10-02 | A kind of Chinese medicine composition for treating lupus nephritis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710962757.2A CN107684608A (en) | 2017-10-02 | 2017-10-02 | A kind of Chinese medicine composition for treating lupus nephritis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107684608A true CN107684608A (en) | 2018-02-13 |
Family
ID=61154468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710962757.2A Pending CN107684608A (en) | 2017-10-02 | 2017-10-02 | A kind of Chinese medicine composition for treating lupus nephritis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107684608A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104825690A (en) * | 2015-05-30 | 2015-08-12 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating lupus nephritis and application thereof |
| CN106309329A (en) * | 2016-10-09 | 2017-01-11 | 上海兰葹生物科技有限公司 | Dendrobe combined eye cream for promoting skin regeneration |
-
2017
- 2017-10-02 CN CN201710962757.2A patent/CN107684608A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104825690A (en) * | 2015-05-30 | 2015-08-12 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating lupus nephritis and application thereof |
| CN106309329A (en) * | 2016-10-09 | 2017-01-11 | 上海兰葹生物科技有限公司 | Dendrobe combined eye cream for promoting skin regeneration |
Non-Patent Citations (3)
| Title |
|---|
| 周宝宽: "狼疮性肾炎验案2则", 《江西中医药》 * |
| 奚智蕾: "中西医结合治疗狼疮性肾炎54例", 《江苏中医》 * |
| 张蕾: "益肾汤治疗隐匿性肾炎50例", 《陕西中医》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tiwari et al. | Immunomodulatory effects of aqueous extract of Tridax procumbens in experimental animals | |
| US20210346281A1 (en) | Multi-component injection | |
| CN101310751B (en) | Detection method of medicine composition for replenishing qi and blood | |
| CN103705754B (en) | A kind of Chinese medicine composition of systemic lupus erythematosus | |
| CN103830577B (en) | A kind of medical composition and its use treating hepatobiliary calculus and urinary stone disease | |
| CN102504043A (en) | Active dendrobe polysaccharide capable of protecting liver and resisting liver fibrosis and preparation method of antibody affinity chromatography | |
| CN104189099A (en) | Application of cistanche phenylethanoid glycoside extractive to control altitude sickness | |
| CN101869656B (en) | Chinese medicinal preparation for treating cough with asthma and preparation method thereof | |
| US6451353B1 (en) | Fagopyrum cymosum (Trev.) Meisn composition, method to prepare and analyze the same and uses thereof | |
| CN103417601A (en) | Pharmaceutical composition capable of adjusting blood fat and applications thereof | |
| CN106596827A (en) | Use of Gal index in assessment of autoimmune disease treatment sensitivity and efficacy | |
| CN102370738B (en) | Chinese medicinal compound preparation for preventing and controlling chronic kidney disease and renal fibrosis, and preparation method thereof | |
| CN107684608A (en) | A kind of Chinese medicine composition for treating lupus nephritis and preparation method thereof | |
| CN104491048B (en) | A kind of loquat leaf total sesquiterpene glucoside extract and preparation method and application | |
| Sairam et al. | Artocarpus altilis-mode of anti-hyperglycemic activity: elucidation by suitable in-vitro and ex-vivo techniques | |
| CN105079143A (en) | Medicine composition for treating nephropathy | |
| CN102475765A (en) | Traditional Chinese medicine composition for improving renal functions and restraining renal fibrosis | |
| CN110201188A (en) | A kind of summer cypress pollen allergen extract, its leaching liquor and preparation method thereof | |
| CN110141602A (en) | A kind of extracting method and application of Folium Mori alkaloid | |
| CN104825690A (en) | Traditional Chinese medicine composition for treating lupus nephritis and application thereof | |
| CN104547514A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus rheumatoid arthritis vasculitis and application thereof | |
| CN105395808B (en) | It is a kind of for treating the synergism medicine composition of diabetes | |
| CN104524338B (en) | A kind of Chinese medicine that treating IgA nephrosis and its application | |
| CN104000938A (en) | Traditional Chinese medicine composition for treating IgA nephropathy and application thereof | |
| CN104547674A (en) | New application of traditional Chinese medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180213 |
|
| RJ01 | Rejection of invention patent application after publication |